MT1A antibodies are primarily polyclonal or monoclonal reagents designed to detect Metallothionein 1A protein in various experimental systems. They are validated for techniques such as immunohistochemistry (IHC), immunofluorescence (IF), Western blot (WB), and enzyme-linked immunosorbent assay (ELISA).
MT1A antibodies are employed in diverse experimental contexts, with specific dilutions and protocols optimized for each technique.
Human Tissue Detection: Positive staining in kidney and liver tissues using TE buffer (pH 9.0) or citrate buffer (pH 6.0) for antigen retrieval .
Cell Line Detection: HeLa cells show cytoplasmic/nuclear localization using Alexa Fluor® 488/594 conjugates .
Quantitative Measurement: Bovine MT1A antibody pair sets use sandwich ELISA for serum, plasma, or tissue lysates .
Oncogenic Potential: MT1A overexpression is linked to tumor progression, angiogenesis, and chemotherapy resistance in cancers (e.g., lung, prostate, cervical) .
Oxidative Stress Response: MT1A upregulation protects cells against reactive oxygen species and heavy metal toxicity .
Biomarker Potential: Serum MT1A levels correlate with tumor staging and prognosis, though species-specific antibodies are required for accurate measurement .
Immunotherapy: MT1A antibodies aid in studying PD-1/PD-L1 interactions and T-cell responses in cancer immunotherapy .
Validation requires a multi-step approach:
Knockout Controls: Use MT1A-deficient cell lines or tissues (e.g., CRISPR-edited models) to confirm absence of signal .
Western Blotting: Verify antibody binds to the expected ~6.1 kDa band under non-reducing conditions .
Immunohistochemistry (IHC): Compare staining patterns with known MT1A-positive/negative tissues (e.g., liver vs. brain) .
Sample Preparation: Metallothioneins are cysteine-rich; avoid β-mercaptoethanol to prevent protein aggregation .
Antibody Clonality: Polyclonal antibodies may detect isoforms (e.g., MT1 vs. MT2), while monoclonals require rigorous isoform validation .
The rs11076161 (A > G) polymorphism alters MT1A expression levels, requiring genotype stratification:
| Genotype | Median MT2 Level (μg/g) | p-Value |
|---|---|---|
| GG (n=37) | 0.194 vs. 0.227 | 0.941 |
| AG (n=31) | 0.237 vs. 0.239 | 0.913 |
| AA (n=4) | 0.174 vs. 0.197 | - |
| Data adapted from endometrial tissue study |
Genotype samples using TaqMan assays (e.g., Thermo Fisher C_1402094_10) before quantitative analysis.
Co-culture Systems: Use MT1A-overexpressing macrophages + T cells to assess cytokine modulation (e.g., IL-10/IL-12 balance) .
Metal Chelation: Deplete zinc with TPEN to isolate MT1A’s metal-independent immunomodulatory effects .
Context-Dependent Analysis:
Single-Cell RNA Sequencing: Resolve cell-type-specific MT1A expression in heterogeneous tissues .
Epitope Divergence: Non-conserved residues in primate MT1A (e.g., position 12: human Lys → primate Glu) .
Solution: Use antibodies raised against primate-specific MT1A peptides (e.g., residues 30-45) .
Cross-Reactivity Check: Pre-incubate antibodies with MT2A to block shared epitopes .
Signal Amplification: Employ tyramide-based systems for low-abundance MT1A in FFPE tissues .